• Oxford PV

  Participated · Series B · Mar 2015

  Oxford Photovoltaics is an Oxford, UK–based spin-out from Oxford University, formed in 2010 by Kevin Arthur. The company is developing a solid-state perovskite solar cell that can be applied as a thin film onto glass building facades. Its core product aims to enable building-integrated photovoltaics by coating glass with thin-film perovskite solar cells. Oxford Photovoltaics raised £8m in the first tranche of a Series B to accelerate development and commercialization toward full-scale production and commercial deployment. Investors in this tranche included new backers from the UK, US, Asia and Europe alongside existing investors such as the University of Oxford, MTI Partners, Longwall Venture Partners, Parkwalk Advisors and a range of angel investors. Oxford Photovoltaics is an Oxford, UK‑based provider of solid‑state dye‑sensitized solar cells for the Building Integrated Photovoltaic (BIPV) sector. The company's cells are made from nontoxic, non‑corrosive materials, can be printed directly onto glass in a range of colours, and are designed to be scalable to any volume. Oxford Photovoltaics commercializes these cells for glazing panels and facades. The company plans to use the recently raised capital to expand its technical and commercial teams and to construct product development and test facilities at Begbroke Science Park near Oxford. Oxford Photovoltaics closed a £2m (≈$3.1m) funding round led by MTI Partners' UMIP Premier Fund with participation from the University of Oxford and private investors. Led by CEO Kevin Arthur, the company is an Oxford University spin‑out. Oxford Photovoltaics is an Oxford University spinout based in Oxford, UK that develops solid-state dye-sensitized solar cells for the Building Integrated Photovoltaic (BIPV) sector. The company focuses on a demonstrator product aimed at BIPV applications. Led by CEO Kevin Arthur, OPV is commercializing technology spun out of Oxford University. OPV completed a £650k funding round to support its next steps. The company intends to use the funds to build its commercial team and scale up demonstrator product manufacturing. Investors in the round include MTI Partners through the UMIP Premier Fund, Parkwalk EIS Technology Fund 1, the World Gold Council and a number of angel investors.

• Cable-Sense

  Led · Equity · Dec 2012

  Cable-Sense is a Lancaster, UK-based network cabling infrastructure company that has developed an intelligent infrastructure management system for cable networks. Its system allows organizations to improve management of their cable networks, reducing energy, capital expenditure and operations costs while improving utilization of assets. The company was founded in 2004 by John Kelly and Tony Peyton and is led by CEO Geoff Butcher. Cable-Sense has worked closely with the School of Electronic and Electrical Engineering at the University of Manchester to bring its products to market. It plans to expand overseas and aimed to triple its turnover by 2014. The company recently raised equity funding and intends to use the capital to hire additional staff in sales, marketing and product development. CableSense develops a patent‑protected technology for non‑invasive interrogation of the physical layer of networked infrastructure, enabling cable status and connectivity to be determined without disrupting connections or information integrity. Its products are cable scanners intended for use in telecommunications rooms and office server environments to automate management of large‑scale structured cabling systems. The company said it will use the award to accelerate delivery of its proposition to market. Financially, the article notes a recent £500K equity investment from MTI Partners via the UMIP Premier Fund. In January 2010 CableSense was awarded a £213K Grant for Research and Development by the Northwest Regional Development Agency. The grant is part of the GRAND programme within the UK Government's Solutions for Business support, funded by the European Regional Development Fund and the NWDA.

• Bioxydyn

  Participated · Equity · Oct 2012

  BiOxyDyn is based at Manchester Science Park and was founded by Prof. Geoff Parker as a spin-out from the University of Manchester and UMIP’s Proof of Principle programme. The company has developed technology used in conjunction with MRI scans to produce better quality images, particularly of the lungs for diseases such as COPD and asthma. It is also active in developing new imaging tools for oncology and neuroscience. BiOxyDyn secured a £1.2m investment from The North West Fund for Biomedical (managed by SPARK Impact) and MTI Ventures’ UMIP Premier Fund (UPF). The company intends to use the funding to expand its imaging service business and to develop its technology into a diagnostic product. BiOxyDyn has developed an innovative approach to 3D lung imaging using enhanced magnetic resonance imaging (MRI) that exposes patients to zero radiation compared with CT scans. The company’s lung scans are positioned to aid diagnosis and monitoring of Chronic Obstructive Pulmonary Disease (COPD) and asthma. BiOxyDyn is based in the Core Technology Facility at the University of Manchester. The company has opened negotiations with a major pharmaceutical company, indicating potential commercial or collaborative opportunities. Financially, BiOxyDyn has received an undisclosed financing from MTI Partners’ UMIP Premier Fund. The deal was reported alongside a prior MTI investment in a different University of Manchester spin-out, Ai2.

• Ai2 UK

  Participated · Equity · Jan 2012

  Ai2 Limited is a Manchester University spin-out that has developed proprietary human protein-like substances which inhibit bacteria, fungi and viruses. Its products are intended to prevent infection on a wide range of medical devices such as urinary catheters and stents, and to be used in wound dressings and consumer products. The company is led by CEO Dr Jim McNairney. Ai2 will use the funds to continue to develop its technology. The article reports the company raised £1.75m in funding to support its development work. Backers named include managers of The North West Fund for Biomedical, SPARK Impact and MTI Firms (managers of UMIP Premier Fund). Ai2 Limited is a Manchester, UK–based developer of technology designed to prevent infection on a wide range of commonly used medical devices, including urinary catheters, stents and wound dressings. The company’s core platform targets microbial contamination across multiple device types and application areas. Recent financing is intended to progress the technology platform and to support alliances and partnerships to test specific applications such as contact lenses and wound dressings. Ai2 has previously received a £100,000 Grant for Research and Development (GRAND) in September 2009. The company’s founder and director, Dr. Curtis Dobson, said the funding will allow Ai2 to build on successes to date and implement and validate the technology in the hands of partners. The firm frames clinical infection as a serious problem and positions its platform as a potential lasting solution.

• PowerOasis

  Participated · Equity · Dec 2011

  PowerOasis develops a wireless network power management platform that remotely monitors, controls and manages the supply of power to base station sites lacking a reliable electricity grid in the Middle East and Africa. The company was co-founded in 2008 by CTO Pete Bishop and is led by CEO John O’Donohue. PowerOasis is based in Swindon, UK and serves wireless operators in regions with unreliable grid power. It has secured growth funding to accelerate commercial deployment and further product development. The recent funding will be used to accelerate sales and product development efforts. No operating metrics were disclosed in the article.

No current team members are available.